Literature DB >> 3932205

Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease.

L Choromanski, R E Kuhn.   

Abstract

Mice infected with Trypanosoma cruzi develop an early and profound immunosuppression of responses to heterologous antigens. Recently it has been demonstrated that this immunosuppression is linked, in part, to deficiency in the production of interleukin 2 (IL-2), and that the addition of IL-2 to cultures of normally unresponsive spleen cells from infected mice will restore responsiveness to sheep erythrocytes (SRBC) and enhance parasite-specific immune responses. In the present study, the effect of administration of ultrapure or recombinant IL-2 on immune responses to SRBC and parasite-specific responses in vivo was examined. It was found that a single injection of 1,500 U of IL-2 provided at the same time as SRBC more than doubled the number of direct plaque-forming cells to SRBC and that multiple injections of 1,500 U of IL-2 were no more restorative than a single injection. Anti-SRBC responses of normal mice were unaffected by injection of IL-2. Single or multiple injections of recombinant human IL-2, with and without gelatin, into highly susceptible C3H(He) mice induced greater parasite-specific immunity as reflected by significantly reduced levels of parasitemia and increased longevity. Three injections of 1,500 U each of recombinant human IL-2 on days 10, 14, and 18 was found to be the most efficacious in reducing parasitemia and increasing longevity. Injection of IL-2 with gelatin did not enhance the effect of IL-2 alone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932205      PMCID: PMC261956          DOI: 10.1128/iai.50.2.354-357.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

2.  The effect of BCG on the course of experimental Chagas' disease in mice.

Authors:  R E Kuhn; R T Vaughn; G A Herbst
Journal:  Int J Parasitol       Date:  1975-10       Impact factor: 3.981

3.  Trypanosoma cruzi: effect on B-cell-responsive and -responding clones.

Authors:  D S Cunningham; R E Kuhn; R L Tarleton; R S Dunn
Journal:  Exp Parasitol       Date:  1981-04       Impact factor: 2.011

4.  Trypanosoma cruzi: immune destruction of parasitized mouse fibroblasts in vitro.

Authors:  R E Kuhn; J E Murnane
Journal:  Exp Parasitol       Date:  1977-02       Impact factor: 2.011

Review 5.  Interleukin 2.

Authors:  K A Smith
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

6.  Suppressor cells present in the spleens of Trypanosoma cruzi-infected mice.

Authors:  C Ramos; I Schädtler-Siwon; L Ortiz-Ortiz
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

7.  Trypanosoma cruzi-induced suppression of the primary immune response in murine cell cultures to T-cell-dependent and -independent antigens.

Authors:  D S Cunningham; R E Kuhn
Journal:  J Parasitol       Date:  1980-02       Impact factor: 1.276

8.  In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.

Authors:  S H Hefeneider; P J Conlon; C S Henney; S Gillis
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

9.  Immunologic deficiency during experimental Chagas' disease (Trypanosoma cruzi infection): role of adherent, nonspecific esterase-positive splenic cells.

Authors:  F Kierszenbaum
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

10.  Treatment of immunodeficiency with interleukin-2: initial exploration.

Authors:  R Mertelsmann; K Welte; C Sternberg; R O'Reilly; M A Moore; B D Clarkson; H F Oettgen
Journal:  J Biol Response Mod       Date:  1984-10
View more
  18 in total

Review 1.  Use of immune modulators in nonspecific therapy of bacterial infections.

Authors:  M T Vogels; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Repeated antigenic stimulation overcomes immunosuppression in experimental Chagas' disease.

Authors:  L Choromanski; R E Kuhn
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

Review 3.  Immunological aspects of fungal pathogenesis.

Authors:  G S Deepe; W E Bullock
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

4.  Antigen-specific T-helper cells abrogate suppression in Trypanosoma cruzi-infected mice.

Authors:  D M Ritter; R E Kuhn
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

5.  Trypanosoma cruzi immunosuppressive factor decreases the interleukin-2 mRNA level in cultured normal activated human lymphocytes.

Authors:  S Majumder; F Kierszenbaum
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  Selective suppressive effects of Trypanosoma cruzi on activated human lymphocytes.

Authors:  L A Beltz; F Kierszenbaum; M B Sztein
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

7.  Effect of elevated environmental temperature on the antibody response of mice to Trypanosoma cruzi during the acute phase of infection.

Authors:  K A Dimock; C D Davis; R E Kuhn
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

8.  Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria.

Authors:  K T Chong
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

9.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

10.  Suppression by Trypanosoma brucei rhodesiense of the capacities of human T lymphocytes to express interleukin-2 receptors and proliferate after mitogenic stimulation.

Authors:  F Kierszenbaum; S Muthukkumar; L A Beltz; M B Sztein
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.